Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01019161
Other study ID # D1531C00012
Secondary ID
Status Completed
Phase Phase 1
First received November 23, 2009
Last updated October 19, 2010
Start date November 2009
Est. completion date June 2010

Study information

Verified date October 2010
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited Kingdom: National Health ServiceUnited Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of the study is to assess how AZD1152 is absorbed or excreted in and out of the body in patients with Acute Myeloid Leukaemia (AML).


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date June 2010
Est. primary completion date June 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with relapsed or refractory AML for which no standard therapies are anticipated to result in durable remission. Or, patients with newly diagnosed AML who are not considered to be suitable for standard induction and consolidation chemotherapy

- Ability to stay in hospital for up to 9 days on the [14C] AZD1152 treatment cycle.

- Subjects who have relapsed > 1 year following myeloablative therapy with allogeneic bone marrow or stem cell transplantation may be eligible if they have no or limited evidence of extensive graft-versus-host disease

Exclusion Criteria:

- QTc interval =470 ms calculated from a single ECG reading or a mean of 3 ECG readings using Fridericia's or Bazett's correction

- Administration of hydroxyurea to control peripheral blood counts is prohibited within 24 hours prior to first dose of study drug

- Any chemotherapy or radiotherapy within 14 days prior to starting the study (not including palliative radiotherapy at focal sites)

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
AZD1152
100mg Lyophile, 5mL Diluent IV infusion
C14 AZD1152
radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion

Locations

Country Name City State
United Kingdom Research Site Manchester

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The concentration of total radioactivity, AZD1152 and AZD1152 hQPA in plasma and their ratios, the concentration of total radioactivity in blood and its blood/plasma concentration ratios Day1-10 No
Primary The derived plasma and urinary pharmacokinetic parameters for AZD1152 and AZD1152 hQPA The percentage of the [14C] AZD1152 dose recovered in urine, faeces and vomit (if presented), and the percentage of radioactive dose recovered overall. Day1-10 No
Secondary Adverse events (AEs), serious adverse events (SAEs) and deaths, Discontinuations for tolerability reasons, vital signs (temperature, blood pressure [BP], pulse rate and respiratory rate [RR]) AEs, SAEs, deaths, discontinuations ongoing to completion and vitals over 22 days - Screening, PD Day 1, Days 3, 6, 9, 14, 22 Yes
Secondary Electrocardiogram (ECG) parameters Screening, PD Day 1, Day 4 Yes
Secondary Clinical chemistry, haematology (including clotting parameters) and urinalysis; physical examination Chemistry/Heamatology - Screening, PD Day 1, Days 3, 6, 9, 14, 22Urinalysis - Screening, PD Day 1 Yes
See also
  Status Clinical Trial Phase
Recruiting NCT02272478 - Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations Phase 2/Phase 3
Completed NCT03672695 - Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia. Phase 1
Completed NCT00530699 - Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML) Phase 1
Not yet recruiting NCT06326697 - Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) Phase 1
Completed NCT01597219 - Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers Phase 2
Completed NCT01063660 - Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML) Phase 2
Terminated NCT05712278 - A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Terminated NCT03217838 - Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. Phase 1
Withdrawn NCT04106076 - Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia Phase 1
Active, not recruiting NCT04217278 - A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT Phase 2/Phase 3
Completed NCT02844257 - Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid Leukaemia N/A
Active, not recruiting NCT01716364 - Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Recruiting NCT06345365 - MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Phase 3
Completed NCT01422603 - Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) Phase 1/Phase 2
Completed NCT04629443 - Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia Phase 1/Phase 2
Recruiting NCT02189824 - Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation Phase 1
Recruiting NCT02724163 - International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia Phase 3
Completed NCT01621724 - WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study Phase 1/Phase 2
Completed NCT01236144 - A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. Phase 1/Phase 2
Completed NCT01497002 - Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a Phase 3